Kyntra Bio director granted 7,000 stock options

KYNTRA BIO, INC. director James A. Schoeneck received a grant of stock options covering 7,000 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

KYNTRA BIO, INC. director James A. Schoeneck received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036.

The 7,000 options vest in four equal quarterly installments starting from the grant date. Following this award, Schoeneck holds 7,000 derivative securities directly in the form of these stock options.

Insider Trade Summary

Grant/Award: 7,000 shares

Grant/Award 1 txn

Insider Schoeneck James A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,000 contracts (Direct)

Footnotes (1)

F1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Key Figures

Options granted: 7,000 options Exercise price: $7.13 per share Underlying shares: 7,000 shares +3 more

6 metrics

Options granted 7,000 options Stock Option (Right to Buy) grant on June 12, 2026

Exercise price $7.13 per share Conversion or exercise price of stock options

Underlying shares 7,000 shares Common Stock underlying the stock options

Expiration date June 11, 2036 Option expiration for the granted stock options

Holdings after grant 7,000 derivative securities Total stock options held following the transaction

Vesting schedule Four equal quarterly installments Measured from the date of grant per footnote

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in four equal quarterly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) reported as a derivative"

exercise price financial

"conversion_or_exercise_price of the option is 7.1300 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date for the stock option is 2036-06-11"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in four equal quarterly installments financial

"shares subject to the option shall vest in four equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KYNTRA BIO (KYNB) report in this Form 4 filing?

KYNTRA BIO reported that director James A. Schoeneck received a grant of stock options for 7,000 shares of common stock. These options are a compensation-related award, not an open-market stock purchase or sale.

How many KYNTRA BIO (KYNB) stock options were granted to James A. Schoeneck?

James A. Schoeneck was granted stock options covering 7,000 shares of KYNTRA BIO common stock. This grant is reflected as a derivative security position and represents his total option holdings following the reported transaction.

What is the exercise price of the KYNTRA BIO (KYNB) options granted?

The stock options granted to James A. Schoeneck have an exercise price of $7.13 per share. This is the price he would pay per share to convert the options into KYNTRA BIO common stock in the future.

When do James A. Schoeneck’s KYNTRA BIO (KYNB) options vest?

The 7,000 stock options vest in four equal quarterly installments measured from the grant date. This means portions of the award become exercisable over four quarters rather than all at once.

When do the newly granted KYNTRA BIO (KYNB) stock options expire?

The stock options granted to James A. Schoeneck expire on June 11, 2036. After that expiration date, any unexercised options will no longer be usable to acquire KYNTRA BIO common shares.

Is this KYNTRA BIO (KYNB) Form 4 transaction a market buy or sell?

No. The Form 4 shows a grant of stock options classified as an acquisition through grant or award. It is a compensation event, not an open-market purchase or sale of KYNTRA BIO shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 07:39 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoeneck James A

(Last)

(First)

(Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO

CALIFORNIA

94133

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.13	06/12/2026		A		7,000		⁽¹⁾	06/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

	/s/ John Alden, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR